- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
December 4, 2019State of Minnesota Sues JUUL
-
November 26, 2019Minnesota Lawyer Honors Two Robins Kaplan Attorneys as 2019 Attorneys of the Year
-
November 21, 2019Firm, Attorney Stacey Slaughter Recognized by National Law Journal
-
December 13, 2019Bridgeport 2019 Wage & Hour Litigation & Management Conference
-
January 10, 2020Bridgeport 2020 Consumer Class Action Litigation Conference
-
January 15-17, 2020Loss Executives Association 89th Annual Meeting and Mid-Winter Educational Program
-
November 2019CLASS ACTION: Experts weigh in on significant class action developments
-
November 15, 20192019 Case Developments: Are Massachusetts Insurers Required To Be Perfect In An Imperfect World?
-
November 15, 2019Artificial Intelligence v. General Data Protection Regulation: Complex Risks in Changing Times
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
September 22, 2019
Weaponizing IPRs
Landslide
August 29, 2019
Resolving Patent Disputes
Financier Worldwide
July 1, 2019
May 20, 2019
Adapt Your IP Strategy for Artificial Intelligence
Robins Kaplan LLP
February 5, 2019
Related News
September 16, 2019
July 26, 2019
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.